Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía Morales, Victoria
dc.contributor.authorGonzález Acedo, Anabel 
dc.contributor.authorMelguizo Rodríguez, Lucía Raquel 
dc.contributor.authorCostela Ruiz, Víctor Javier 
dc.contributor.authorMontiel Troya, María 
dc.contributor.authorRamos Rodríguez, Juan José 
dc.date.accessioned2022-01-27T11:42:40Z
dc.date.available2022-01-27T11:42:40Z
dc.date.issued2021-12-14
dc.identifier.citationGarcía-Morales, V... [et al.]. Current Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer’s Disease. Biomedicines 2021, 9, 1910. [https://doi.org/10.3390/biomedicines9121910]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/72521
dc.descriptionL.M.-R. and J.J.R.-R. are funded by P20-01293 from Junta de Andalucia, Spain. J.J.R.-R. is additionally funded by PECART-0096-2020 from Junta de Andalucia, Spain and PID2020-117544RB-100 from the Ministry of Science and Innovation, Spain.es_ES
dc.description.abstractAlzheimer's disease (AD) is the most common cause of dementia. It is characterized by cognitive decline and progressive memory loss. The aim of this review was to update the state of knowledge on the pathophysiological mechanisms, diagnostic methods and therapeutic approach to AD. Currently, the amyloid cascade hypothesis remains the leading theory in the pathophysiology of AD. This hypothesis states that amyloid-beta (A beta) deposition triggers a chemical cascade of events leading to the development of AD dementia. The antemortem diagnosis of AD is still based on clinical parameters. Diagnostic procedures in AD include fluid-based biomarkers such as those present in cerebrospinal fluid and plasma or diagnostic imaging methods. Currently, the therapeutic armory available focuses on symptom control and is based on four pillars: pharmacological treatment where acetylcholinesterase inhibitors stand out; pharmacological treatment under investigation which includes drugs focused on the control of A beta pathology and tau hyperphosphorylation; treatment focusing on risk factors such as diabetes; or nonpharmacological treatments aimed at preventing development of the disease or treating symptoms through occupational therapy or psychological help. AD remains a largely unknown disease. Further research is needed to identify new biomarkers and therapies that can prevent progression of the pathology.es_ES
dc.description.sponsorshipJunta de Andalucia European Commission P20-01293 PECART-0096-2020es_ES
dc.description.sponsorshipSpanish Government European Commission PID2020-117544RB-100es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectAlzheimer's disease es_ES
dc.subjectSenile plaqueses_ES
dc.subjectbeta-amyloid proteines_ES
dc.subjectTau proteines_ES
dc.subjectDiagnosis es_ES
dc.subjectBiomarkeres_ES
dc.subjectTreatment es_ES
dc.subjectAcetylcholinesterase inhibitorses_ES
dc.subjectImmunotherapy es_ES
dc.titleCurrent Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer’s Diseasees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/biomedicines9121910
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España